Search Results

41 - 50 of 60 items :

  • Clinical Medicine x
  • BY LANGUAGE: English x
Clear All

-intervention evaluations of randomized controlled trials) and case–control studies were included in the analysis. The methodological quality of the cross-sectional studies was assessed using an 11-item checklist as recommended by the Agency for Healthcare Research and Quality.[ 16 ] An item received a score of “0” if answered as “NO” or “UNCLEAR”; if answered as “YES,” the item received a score of “1.” The quality of an article was assessed based on the score as follows: low quality = 0−3; moderate quality = 4−7; high quality = 8−11. The quality of case–control studies was assessed by

warfarin 2.5 mg daily and afterwards titrated to achieve INR target range 2.0–3.0. Approximately 83% of the study population started anticoagulant treatment within 3 months since PVT diagnosis. Untreated patients during the same period (between 2002–2014) constituted the control group. Recanalization was significantly more frequent in treated patients (68.2% vs . 25%).[ 23 ] Finally, a propensity score matching the analysis of 14 cirrhotic patients with PVT who received warfarin and 14 patients who were not anticoagulated confirmed higher rates of recanalization in the

asunaprevir (ASV; NS3/4A protease inhibitor) for patients with HCV genotype 1b. DCV/ASV therapy increased the sustained virological response (SVR) rate to about 90% and caused less adverse effects than IFN-based therapy.[ 3 – 7 ] In Japan, DCV/ASV therapy can be administered to patients with chronic hepatitis or compensated cirrhosis with a Child-Pugh score of 6 or less, but not to those with decompensated cirrhosis with a Child-Pugh score of 7 or more. In some other countries, IFN-free therapy is authorized for patients with decompensated cirrhosis, and high SVR rates are

patients with cirrhosis Thromb Res 2013 131 173 77 5 Zocco MA, Di Stasio E, De Cristofaro R, Novi M, Ainora ME, Ponziani F, et al . Thrombotic risk factors in patients with liver cirrhosis: Correlation with MELD scoring system and portal vein thrombosis development. J. Hepatol 2009;51: 682-9. Zocco MA Di Stasio E De Cristofaro R Novi M Ainora ME Ponziani F Thrombotic risk factors in patients with liver cirrhosis: Correlation with MELD scoring system and portal vein thrombosis development J. Hepatol 2009 51 682 9 6 Amitrano L, Guardascione MA, Ames PR, Margaglione M

of the Surgeon General Atlanta U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health 2014 7 Hajifathalian K, Ueda P, Lu Y, Woodward M, Ahmadvand A, AguilarSalinas CA, et al . A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys. Lancet Diabetes Endocrinol 2015; 3: 339–55 Hajifathalian K Ueda P Lu Y Woodward M Ahmadvand A

consecutively enrolled in the study. The study was conducted at the Sindh Institute of Urology and Transplantation (SIUT), Karachi, Pakistan, a large tertiary care center that caters to a significant number of dialysis patients from all over Pakistan. Dyspepsia was labelled after using the LDQ questionnaire, in those with a score equal or greater than 5 over the period of last four weeks.[ 7 ] Since the LDQ is long and cumbersome, and was not designed for self-completion, we modified the questionnaire for use in our setting. The LDQ questionnaire originally comprised of 9

cancer dexamethasone treatment was started according to the established prescription policy. [ 3 ] The most common specific indications for treatment with dexamethasone were spinal cord compression, cerebral metastases, lymphangitic carcinomatosis, and bowel obstruction. The most common nonspecific indications comprised anorexia, nausea, low mood, pain, and vomiting. The median duration of steroid use was 21.5 days (range: 1–89 days). Symptom scores improved during the therapy compared with the baseline in most patients for anorexia, nausea, pain, low mood, vomiting

. The ABCs of DKA: Development and Validation of a Computer-Based Simulator and Scoring System. J Gen Intern Med 2015; 30: 1319-32. Yu CH Straus S PhD RB The ABCs of DKA: Development and Validation of a Computer-Based Simulator and Scoring System J Gen Intern Med 2015 30 1319 32 7 Gosmanov AR, Gosmanova EO, Dillard-Cannon E. Management of adult diabetic ketoacidosis. Diabetes Metab Syndr Obes 2014; 7: 255-64. Gosmanov AR Gosmanova EO Dillard-Cannon E Management of adult diabetic ketoacidosis Diabetes Metab Syndr Obes 2014 7 255 64 8 Basnet S, Venepalli PK, Andoh J

Caucasians named Hoffstein formula. The predictive equation was shown as follows: predicted pressure (cm H 2 O) = 6.656 + 0.156 × (body mass index [kg/m 2 ]) – 0.071 × (minimal SpO 2 [%]) + 0.041 × (respiratory disturbance index) + 0.094 × (score of Epworth Sleepiness).[ 8 ] Noteworthy, this formula provided an optimal estimation of CPAP pressure for a low proportion of subjects (38%), thus the predictive equation is not a sufficient substitute for the manual CPAP titration. But the use of the CPAP prediction formula may improve manual CPAP titration success by customize

schistosomiasis: Fibrosis and treatment response World J Gastroentrol 2013 19 2691 6 21 Alboraie M, Khairy M, Elsharkawy M, Asem N, Elsharkawy A, Esmat G. Value of Egy-Score in diagnosis of significant, advanced hepatic fibrosis and cirrhosis compared to aspartate aminotransferase-to-platelet ratio index, FIB-4 and Forns’ index in chronic hepatitis C virus. Hepatol Res 2015; 45: 560-70. Alboraie M Khairy M Elsharkawy M Asem N Elsharkawy A Esmat G. Value of Egy-Score in diagnosis of significant, advanced hepatic fibrosis and cirrhosis compared to aspartate aminotransferase